ADC Therapeutics SA Form 6-K Summary
Business Context and Reporting Period
ADC Therapeutics SA furnished this Form 6-K for August 2023. On August 30, 2023, the company announced updated safety run-in results from the LOTIS-5 Phase 3 confirmatory trial evaluating ZYNLONTA (loncastuximab tesirine) in combination with rituximab (Lonca-R) for patients with relapsed or refractory diffuse large B-cell lymphoma.
Clinical and Other Key Metrics
- The safety run-in enrolled 20 patients, with a median age of 74.5 years.
- Patients had received a median of five cycles of Lonca-R and one prior therapy.
- Overall response rate by central review was 16 of 20 patients, or 80%.
- Complete response was achieved by 10 of 20 patients, or 50%; partial response was achieved by 6 of 20 patients, or 30%.
- Median duration of response was 8.0 months, and median progression-free survival was 8.3 months.
- Seven patients had completed treatment and five remained in follow-up as of the April 10, 2023 data cutoff.
- Eleven patients, or 55%, experienced grade 3 or higher treatment-emergent adverse events. The most common were increased gamma-glutamyltransferase in five patients, or 25%, and neutropenia in three patients, or 15%.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other corporate financial metrics.
Material Changes, Outlook, and Risks
These were updated safety run-in results; the filing does not provide a prior comparable clinical dataset or quantify changes versus an earlier period.
LOTIS-5 is a randomized, open-label, two-part Phase 3 study. Part 2 is expected to randomize approximately 330 patients on a 1:1 basis to fixed-dose Lonca-R or rituximab-gemcitabine-oxaliplatin. The trial is intended to serve as the confirmatory study for ZYNLONTA’s accelerated approval in third-line-or-later treatment and could support a potential second-line-plus label expansion in combination with rituximab.
Important risks include the small size of the safety run-in, the absence of a randomized comparator in Part 1, clinically significant grade 3 or higher adverse events, and the uncertainty that the confirmatory trial will validate the reported activity or support regulatory approval or label expansion. The filing does not provide additional guidance, financial outlook, or contingency information.
Investor Verification Priorities
- Verify the April 10, 2023 data cutoff and whether subsequent LOTIS-5 data materially changed the efficacy or safety profile.
- Assess results from the randomized portion of LOTIS-5, including the comparison with R-GemOx.
- Review the severity, duration, and management of hepatotoxicity, neutropenia, and other treatment-emergent adverse events.
- Confirm the regulatory status and conditions of ZYNLONTA’s accelerated approval and any potential label expansion.
- Consult the company’s financial filings for cash runway, liquidity, debt, revenue, operating losses, and funding requirements, which are not addressed in this Form 6-K.